A TSHR-LH/CGR Chimera that Measures Functional Thyroid-Stimulating Autoantibodies (TSAb) Can Predict Remission or Recurrence in Graves' Patients Undergoing Antithyroid Drug (ATD) Treatment | Zendy

Cesidio Giuliani | Zendy; Dominique Cerrone | Zendy; Norikazu Harii | Zendy; Mark Thornton | Zendy; Leonard D. Kohn | Zendy; Nilesh M. Dagia | Zendy; Ines Bucci | Zendy; Maria Carpentieri | Zendy; Barbara Di Nenno | Zendy; Andrea Di Blasio | Zendy; Paolo Vitti | Zendy; Fabrizio Monaco | Zendy; Giorgio Napolitano | Zendy

Open Access

A TSHR-LH/CGR Chimera that Measures Functional Thyroid-Stimulating Autoantibodies (TSAb) Can Predict Remission or Recurrence in Graves' Patients Undergoing Antithyroid Drug (ATD) Treatment

Author(s) -

Cesidio Giuliani,

Dominique Cerrone,

Norikazu Harii,

Mark Thornton,

Leonard D. Kohn,

Nilesh M. Dagia,

Ines Bucci,

Maria Carpentieri,

Barbara Di Nenno,

Andrea Di Blasio,

Paolo Vitti,

Fabrizio Monaco,

Giorgio Napolitano

Publication year - 2012

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2011-2897

Subject(s) - medicine , graves' disease , endocrinology , autoantibody , thyroid , antithyroid agent , hormone , thyroid stimulating hormone , receptor , antibody , immunology

A functional thyroid-stimulating autoantibodies (TSAb) assay using a thyroid-stimulating hormone receptor chimera (Mc4) appears to be clinically more useful than the commonly used assay, a binding assay that measures all the antibodies binding to the thyroid-stimulating hormone receptor without functional discrimination, in diagnosing patient with Graves' disease (GD).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research